FLT3 and acute myeloid leukemia: It was also underlined by multivariate analysis that allo-HSCT in CR1 is the only prognostic factor capable of giving a better OS and progression-free survival (PFS), demonstrating that prognosis was unfavorable in NPM1-mutated AML with FLT3-ITDlow AR when allo-HSCT was not carried out in CR1 [54].